Abstract:Abstract Introduction: Neoadjuvant systemic therapy (NAT) has been the standard-of-care of stage II-III, locally advanced triple-negative breast cancer (TNBC). However, about 50% of TNBC patients achieve a pathological complete response (pCR) to conventional neoadjuvant chemotherapy (NAC)1. Recently approved combination of NAC with the immunotherapy pembrolizumab, has improved the pCR rate by 7.5%2, although with a 44% risk of immune-related adverse reaction3. Aside from the need to develop new therapies with higher efficacy and lower toxicity, a critical barrier to improving TNBC response is the lack of rigorous ways to personally tailor therapeutic regimens. We seek to address this challenge by employing digital twins (i.e., mathematical models that provide virtual representation of individual patients and predict the changes at future time points) to systematically evaluate individual TNBC patient’s response to different NAT regimens, thereby patient-specifically optimizing treatments. Methods: A TNBC cohort (n = 139) from the ARTEMIS trial (NCT02276433)4 was used for this study. All patients received 4 cycles of Adriamycin/Cytoxan (A/C) every 2 weeks, followed by 12 cycles of weekly Taxol or experimental therapy in Phase II trials. All patients had surgery after NAT and post-surgical pathology to assess response status. For each patient, longitudinal MRIs were collected before, during, and after A/C. We have developed digital twins to integrate the longitudinal MRIs with a mechanism-based model to accurately predict TNBC response5. The model was based on a reaction-diffusion equation that describes the change in tumor cellularity due to migration, proliferation, and drug-induced death. With parameters personalized using MRIs, the patient-specific model (i.e., digital twin) significantly improved the accuracy to predict pCR5. We investigated patient-specific treatment optimization on 37 (19 pCR, 18 non-pCR) chemo-sensitive patients (≥ 70% volume decrease after A/C) who received only NAC. We evaluated the effect of altering the A/C/Taxol schedules on patient response. Specifically, each patient’s digital twin was used to predict the patient’s response to 128 clinically reasonable schedules of A/C/Taxol; i.e., 8 candidate A/C schedules combining with 16 candidate Taxol schedules (Table 1). The predicted response (pCR or non-pCR) from each alternative schedule was compared to the patient response from the actual treatment. Results: Without changing the total dose, shortening the duration of A/C/Taxol administration increased the treatment efficacy. The effectiveness of altering the schedules varied substantially in different patients. In particular, 8 patients who had non-pCR responses to their actual treatment were predicted to achieve pCR with the dense-dose Taxol (i.e., 4 cycles Taxol, 2 weeks per cycle), indicating a 21.62% improvement of pCR rate in the cohort. Discussion and conclusion: The preliminary results with our digital twin approach provided a unique opportunity of improving TNBC response to NAT through patient-specific optimization of therapeutic schedules. The ongoing effort focuses on accounting for toxicity and investigating the effects of altering therapy types and doses in combination with the schedules on the patient response. [1] Spring et al., Clin Cancer Res, 2020. [2] Schmid et al., NEJM, 2022. [3] Shah et al., Clin Cancer Res, 2022. [4] Yam et al., Clin Cancer Res, 2021. [5] Wu et al., Cancer Res, 2022. Table 1. Candidate therapeutic schedules Citation Format: Chengyue Wu, Ernesto Lima, Casey Stowers, Zhan Xu, Clinton Yam, Jong Bum Son, Jingfei Ma, Gaiane Rauch, Thomas Yankeelov. Optimizing therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-03-06.

Abstract B023: Modeling of new drugs clinical trials outcome with patients’ digital twins cohorts

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Abstract 7393: Tumor model to tumor treatment: Applying deep learning approaches to map multimodal data from cancer model systems to patients

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

Abstract A014: Deep learning-driven drug discovery: A breakthrough algorithm and its implication in lung cancer therapy development

Abstract 3537: Assessing machine learning models of drug response predictions using orthotopic patient-derived xenograft

Abstract 7365: Drug-centric prior improves drug response signature identification in partially overlapping, large-scale pharmacogenomic datasets

Abstract 7373: Generative Bayesian networks for augmentation of molecular data from commercial genetics panels

Abstract 941: Patient-derived model systems of endometrial cancers for disease modeling and drug sensitivity testing

Abstract PO5-03-06: Optimizing therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy

Abstract 3522: Application of large language models to nucleotide sequences for profiling signaling pathway disruptions in ovarian cancer patients

Abstract 3982: Prediction and Selection of Cancer Drug Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles

Abstract IA021: Digital patient avatars predict cancer evolution and personalised therapeutic strategies

Abstract 2034: Discovery of novel therapeutic targets using 3D chromatin conformation and patient-specific gene regulatory networks

Abstract 1174: Enhancing the utilization of deep learning to predict patient response in small immunotherapy cohorts using real-world data

Abstract 6214: OncodynamiX as an artificial intelligence (AI) based platform for precision medicine

Abstract A017: Computational and mouse models of adaptive therapy with multiple drugs in breast cancer

Optimal Prescriptive Treatments for Ovarian Cancer with Genetic Data

Abstract PR003: Multi-drug adaptive therapy protocol in vitro: An exercise in optimization for neuroblastoma

Abstract 2736: Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin

Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival